Pathophysiology of anemia in chronic kidney diseases: A review

Josef Zadrazil, Pavel Horak

Background. Anemia is one of the laboratory and clinical findings of chronic kidney diseases (CKD). The presence of anemia in patients with CKD has a wide range of clinically important consequences. Some of the symptoms that were previously attributed to reduced renal function are, in fact, a consequence of anemia. Anemia contributes to increased cardiac output, the development of left ventricular hypertrophy, angina, and congestive heart failure. According to current knowledge, anemia also contributes to the progression of CKD and is one of the factors that contribute to the high morbidity and mortality in patients with chronic renal failure and their reduced survival.

Methods. MEDLINE search was performed to collect both original and review articles addressing anemia in CKD, pathophysiology of renal anemia, erythropoiesis, erythropoietin, iron metabolism, inflammation, malnutrition, drugs, renal replacement therapy and anemia management.

Conclusion. The present review summarized current knowledge in the field of the pathophysiology of renal anemia. Understanding the pathophysiology of anemia in CKD is crucial for the optimal treatment of anemia according to recent clinical practice guidelines and recommendation, and correct recognition of causes of resistance to treatment of erythropoietin stimulating agents (ESA).

Key words: anemia, chronic kidney diseases, erythropoietin, iron metabolism, erythropoiesis

INTRODUCTION

Anemia is one of the clinical and laboratory manifestations of CKD. It is defined as a decrease in hemoglobin (HGB) <130g/L in men and HGB <120g/L in women. Relatively little is known about the development and progression of anemia in patients with CKD. As kidney function declines and in patients with more advanced CKD stages, the incidence and prevalence of anemia increased. There is an exponential relationship between decrease glomerular filtration and anemia. Typically, the development of anemia occurs when the glomerular filtration rate drops below 0.5 mL/s, or even below 0.75 mL/s in patients affected by diabetic nephropathy. However, large differences are seen among individual patients in the degree of decline in renal function and severity of anemia. In morphological terms, anemia accompanying advanced kidney disease usually has a normocytic and normochromic pattern, and may be associated with the occurrence of acanthocytes and, possibly, schistocytes1-4.

The presence of anemia in patients with CKD has a wide range of clinically important consequences. Some of the symptoms that were previously attributed to reduced renal function are, in fact, a consequence of anemia. These include, in particular, reduced physical performance, fatigue, shortness of breath, loss of appetite, insomnia, sexual and cognitive function disorders, and reduced immunological reactivity1. Anemia contributes to increased cardiac output, the development of left ventricular hypertrophy, angina, and congestive heart failure4. According to current knowledge, anemia also contributes to the progression of CKD and is one of the factors that contribute to the high morbidity and mortality in patients with chronic renal failure and their reduced survival5.

The present review discusses the pathophysiology of anemia in CKD. It provides details on the physiology and pathophysiology of erythropoietin and iron metabolism and briefly discusses other factors which may be important for the development of anemia (infectious processes, inflammatory conditions, certain medications, secondary hyperparathyroidism, cancer), while the importance of others is only complementary (deficiency of Vitamin B12, folic acid), or more or less hypothetical (e.g. uremic inhibitors of erythropoiesis).

Insufficient erythropoietin production

A relative lack of erythropoietin (EPO) is considered to be the main cause of the development of renal anemia. Erythropoietin is a hormone produced by specialized type I interstitial fibroblasts in the cortex and outer layer of the renal medulla. It is a crucial factor that regulates the size of the red blood cell mass related to its integration into the oxygen transport system6. The main stimulus for elevated synthesis of EPO is tissue hypoxia, which normally leads to an exponential increase in serum EPO levels7,8. This feedback is affected in patients with pathological conditions involving the kidneys and the developing anemia is not adequately compensated by a sufficient increase in the EPO production9,10.
Endogenous EPO is a glycoprotein composed of 165 amino acids with a molecular weight of 30,400 Da. Approximately 39% of the native molecule consists of carbohydrates. The three-dimensional structure of the EPO molecule is determined by four parallel helices, A, B, C and D, which are inter connected by peptide chains of various lengths. The half-life of endogenous EPO is 5 hours.11

The gene that encodes EPO is located on chromosome 7 (q11-q22) (ref.13). The erythropoietin gene transcription is activated by hypoxia-induced factor (HIF-1) (ref.13). It is a basic protein which activates the transcription of all hypoxia-induced genes, i.e., not only erythropoietin, but also vascular endothelial growth factor, platelet derived growth factor, and the glycolytic enzymes, such as aldolase A, enolase-1, lactate dehydrogenase A, phosphofructokinase-1 and phosphoglycerate kinase-1. Hypoxia-induced factor-1 is composed of two units. The HIF-1α subunit is composed of 826 amino acids, whereas the HIF-1β subunit has two isoforms of 774 and 789 amino acids. Experimental studies have shown that with decreasing oxygen concentrations, the activity of HIF-1α and HIF-1β in the Hela cell incubation medium increases exponentially, while under normoxic conditions, subunit HIF-1α is rapidly hydroxylated and degraded.14,15

In the kidneys, which are the main source of EPO, this hormone is produced in the peritubular type I interstitial cells located in the cortex or in the outer layer of the renal medulla between the basolateral membrane of the proximal tubules and peritubular capillaries.6,16,17 Hybridization techniques have confirmed that EPO is not produced for storage, but an increase in its production related to hypoxic stimuli is caused by exponential growth in the number of specialized cells.16,19 The feedback mechanism is highly sensitive because an increase in the activity of specific mRNA can be demonstrated within two hours of the onset of hypoxic stimulus. This method of EPO regulation also allows prompt reduction in EPO production after the resolution of hypoxia.20,21

The most important extrarenal source of EPO is the liver, which accounts for 10-15% of the total EPO production.14 Hybridization techniques have demonstrated that about 80% of EPO is produced in hepatocytes and the remaining 20% in the Ito cells. Hepatocytes, in which specific mRNA was demonstrated, are located near the central vein that is known to have the lowest local oxygen tension in the liver. Ito cells have many similarities to renal fibroblasts and therefore, they are also known as perisinusoidal cells1. It is likely that the mechanism of gene expression for EPO synthesis in the liver is genetically different from the regulation of EPO production in the kidneys. Sensitivity to the hypoxic signal, in terms of the initiation of EPO production, is much lower in the liver than in the kidneys. The hepatic production of EPO may have some biological relevance only in anephric patients with severe and prolonged hypoxia and finally, in cases of hepatocellular regeneration, such as in the recovery phase after viral hepatitis.1,10

The stimulatory effect of EPO on erythropoiesis is mediated by the interaction of EPO with specific receptors on the surface of hematopoietic progenitor cells in the bone marrow, called BFU-E (Burst Forming Unit Erythroid) and CFU-E (Colony Forming Unit Erythroid), which are stimulated for proliferation and differentiation. The erythropoietin receptor is a glycoprotein with 484 amino acid residues. The binding of EPO to its receptor activates the Janus kinase 2 (JAK-2), which subsequently leads to the inhibition of apoptosis of progenitor cells via multiple regulatory processes. The expression of the erythropoietin receptor is controlled during the differentiation of erythroid cells by a highly specialized transcription factor, which is called GATA-1 according to the site of binding to the DNA double helix. Targeted mutation of the GATA-1 gene was used to demonstrate the necessity of this factor for direct control of the expression of the EPO receptors on the surface EPO-sensitive erythropoietic cells.22,23

CFU-E are considered to be the primary target cells of EPO. These cells are sensitive even to small amounts of EPO, and rapidly multiply in the presence of EPO, producing colonies of up to 50 erythroblasts in about 7 days. CFU-E represent about 0.1% of all nucleated cells in the bone marrow and express 300 to 1,000 receptors on the surface of their cell membrane. Under normal circumstances, the majority of CFU-E is eliminated through the mechanism of programmed cell death, but in patients with anemia, the number of cells that are not eliminated and continue in the differentiation increases due to elevated EPO levels. This mechanism allows increasing erythropoiesis quickly and as needed.24 Erythropoietin receptors in the membrane of progenitor cells disappear at the basophilic normoblast stage, since more mature forms of the cells no longer need EPO for further maturation.25

Iron metabolism disorders

Iron deficiency, or its limited availability for erythropoiesis, is an important pathogenetic mechanism for the development of renal anemia. Hepcidin is currently believed to play a crucial role in the regulation of iron metabolism. This hormone was discovered by Krause in the year 2000 (ref.26) and independently by Park in 2001 (ref.27). Bioactive hepcidin is composed of 25 amino acids and is synthesized mainly in hepatocytes. The regulation of iron absorption and its distribution into the tissues is mediated by regulation of the expression of its receptor, ferroportin, which is known to be the sole cellular iron exporter. Hepcidin synthesis is induced by excess iron levels or inflammation, while it is inhibited by increased erythropoiesis or hypoxia. Increased hepcidin levels are known to block iron absorption from food in the intestines and its release from iron stores. The activation of erythropoiesis logically leads to the suppression of hepcidin production and subsequent mobilization of iron from its stores. Synthesis of hepcidin is stimulated by proinflammatory cytokines, in particular IL-6 (ref.28). However, based on current knowledge, determination of hepcidin in the diagnosis of iron deficiency in dialyzed patients is not recommended in routine clinical practice.29

Daily iron loss is small in normal individuals. Iron is lost by the desquamation of skin epithelial cells, intestinal tract mucosa, growth of hair and nails, and partly in
the bile, sweat, and urine. The total iron loss through all these paths in adult males as measured by radioisotope techniques is 0.5 to 1.5 mg daily. Women of childbearing potential in addition lose 30-60 mg of iron with each menstruation and 500 mg of iron with each childbirth. Therefore, the expected daily iron loss in women is about 0.5-1 mg higher than in men.

Under normal circumstances, physiological iron loss is fully compensated by iron reabsorption from food. In dialyzed patients, however, physiological iron loss is increased by a number of other circumstances that could easily induce iron deficiency. The main factor that leads to iron deficiency in dialyzed patients is excessive blood loss during dialysis, especially the significant amount of residual blood that remains inside the dialyzer, dialysis sets, and needles after each hemodialysis. It is generally accepted that the average annual loss of iron in dialyzed patients is 1.5-2.0 g (ref. 30, 31). The normal daily intake of iron is 10 to 15 mg and the maximum absorption is about 20%. Therefore, the amount of iron the body can absorb from regular food is not able to compensate for these substantial losses. Thus, dialyzed patients, who receive no iron supplementation therapy, can very easily develop a negative iron balance and depletion of tissue iron stores.

The body of a healthy adult normally contains 4-5 grams of iron. Iron deficiency is defined as a condition where the amount of iron in the body decreases to a level that is characterized by a depletion of iron stores in bone marrow, liver and spleen and imbalance between the iron supply to the tissues and the real need. Iron deficiency is detected by laboratory methods evaluating the ratio of iron stores and available iron levels. According to the latest knowledge, examination of stainable iron in the bone marrow remains "gold standard" for determining the iron store levels in the body. Lack of iron in the body is indicated by a lack of iron in the cells of the mononuclear phagocyte system and decrease in the sideroblast count below 10% (ref. 34).

Under normal circumstances, storage iron accounts for approximately 30% of the body’s total iron. The main places where iron is deposited are the reticuloendothelial system of the bone marrow, liver, and spleen, and the liver parenchymal cells. Iron is stored as ferritin or hemosiderin. Ferritin was first discovered by Czechoslovak physiologist Vilém Laufberger, who isolated ferritin from the spleen and liver in 1936 (ref. 35). Ferritin is composed of an inorganic core called holoferritin, which is surrounded by a protein envelope. The protein portion of the molecule is known as apoferritin and has 24 subunits, which are designated H and L. Each molecule of apoferritin can bind 2,000 - 4,000 atoms of iron, and the molecular weight of ferritin is approximately 500,000 (ref. 34). The second form of storage iron is iron stored in the form of hemosiderin. Hemosiderin granules are large aggregates of ferritin molecules with higher iron content. Hemosiderin further contains fats and, unlike ferritin, it is soluble in water. Under normal circumstances, iron is primarily stored as ferritin, and the ferritin/hemosiderin ratio is 60:40 (ref. 31, 36).

In 1972, Addison published his observations that serum ferritin (SF) can be detected by immunoradiometric methods and he demonstrated that SF is closely related to the amount of iron in the reticuloendothelial system and is directly proportional to the releasable iron stores in the body. The determination of SF is a relatively simple and reliable examination intended to detect reduced iron stores. When interpreting the serum ferritin concentrations, it should be remembered that SF concentrations are increased independently of the amount of iron stores in some conditions, particularly in manifest and latent infections, liver diseases, or malignant tumors.

For completeness of the present overview of methods, it should be noted that determination of the urinary excretion of iron after the administration of desferrioxamine or determination of the 59Fe2+ reabsorption from the gastrointestinal tract can be used to evaluate the iron status in the body.

To evaluate the functional iron status, we can use a variety of other laboratory parameters, such as iron plasma concentrations (pFe), transferrin, and transferrin saturation (TSAT). Low pFe levels may have many causes and in differential diagnostic terms, it is very important to differentiate low pFe levels due to actual iron deficiency from reactive hyposideremia based on utilization disorder or abnormal iron distribution, as is the case in infectious processes, tissue damage, and malignant tumors.

Organic and ionized forms of iron are highly toxic and rather insoluble and for this reason, the transport of iron in the body is bound to a protein component, transferrin. Transferrin is a glycoprotein with a molecular weight of 79, 550 Da. The main site of transferrin production is the liver. Transferrin has two binding sites for iron, which allow the existence of apoferrin, monoferric, or diferric transferrin, according to the degree of iron saturation. In addition to iron bound in the trivalent form, transferrin can, however, bind other metal ions, of which binding to aluminum may have adverse effects on the erythropoiesis in patients with sideropenic anemia, the ability of the serum to bind iron is increased, and iron deficiency is also a leading cause of elevated transferrin levels. Transferrin is known to control the internal transfer of iron from the place of absorption to the places of iron consumption or deposition, and back, when utilizing the iron released from the disintegrating red blood cells. Circulating iron bound to transferrin in the plasma is transported into cells via receptors expressed on the cell membranes. Binding to the receptors on the cell membrane triggers receptor-mediated endocytosis. In the acidic environment of the cell, iron is released from transferrin and after being reduced by the effects of mitochondrial ferrochelatase, it is incorporated into the heme. The final phase is exocytosis of apotransferrin back into the blood plasma. Iron deficiency results in a compensatory increase in the number of transferrin receptors and their serum concentration is also increased.

As with pFe, the transferrin concentrations are also influenced by a variety of clinical conditions. Transferrin levels are reduced by acute and chronic infections, malignancies, collagenosis, hemolytic anemia, or hypopro-
teinemia. Since pFe and transferrin are subject to numerous reactive changes under various pathological conditions, the relationship between these two values, known as TSAT, is considered to be a more accurate indicator of the metabolic status of iron. TSAT levels are calculated according to the following formula:

\[
\text{Transferrin saturation (TSAT) (\%)} = \left( \frac{\text{pFe (\mu mol/L)}}{\text{Transferrin (\mu mol/L)}} \right) \times 100
\]

Under physiological conditions, the binding capacity of transferrin is 20-45% saturated with iron. Decreased transferrin saturation is one of the indicators of iron deficiency. Iron is most efficiently uptaken by erythroblasts at 30-60% transferrin saturation. If the saturation exceeds 60%, iron is stored in the mononuclear phagocyte system cells.

Diagnostic tests for functional iron status assessment are complemented by percentage of hypochromic red blood cells, erythrocyte zinc protoporphyrin testing, or serum transferrin receptor levels, which are subject to a compensatory increase in patients with iron deficiency. These tests are used much less in clinical nephrology and their validity in patients with CKD has not been characterized reliably.

Other factors contributing to the development of anemia

Gradually, multiple other factors have been identified that may further exacerbate anemia developing in patients with impaired renal function. Some of these factors may be important for the development of anemia (e.g., inflammatory processes or tumors), while the meaning of others is only coincidental (e.g., folic acid or drugs), or more or less hypothetical (e.g. uremic inhibitors of erythropoiesis).

Suppression of erythropoiesis occurs during severe infectious processes, inflammatory diseases, and malignancies. Inflammation is often accompanied by malnutrition and both have a significant role in the development of anemia. We are talking about the MIA syndrome (malnutrition, inflammation, anemia). The main causes are: increased production of certain cytokines, such as IL-1, IL-6, TNF-alpha, and interferon-gamma that block the release of iron from iron stores, reduce the production of endogenous EPO, and suppress erythropoiesis. Inflammation increased uptake of the iron within cells of the reticuloendothelial system. This leads to limitation of iron availability for erythroid progenitor cells and subsequently decreased erythropoiesis. A key role in this chronic inflammation-related anemia is played by hepcidin, whose synthesis and serum levels increase up to 100-fold during inflammation. In the laboratory, this condition is confirmed by increased SF concentrations, and reduced pFe, transferrin levels, and TSAT.

In patients with renal disease, reduced intravascular survival of red blood cells is caused by chronic hemolysis, which is the result of accumulation of hypothetical uremic toxins in the blood. The survival of red blood cells in patients with chronic renal failure can be normalized by the transfusion of erythrocytes from healthy people.

The most important uremic toxins in the pathophysiology of renal anemia are polyamines, such as spermine, spermidine, putrescine, and cadaverine. Polyamines are organic cations involved in cell growth and maturation that reduce the proliferative activity of erythroid cells in the bone marrow by a direct toxic effect that is independent on their interaction with EPO.

Research on uremic toxins and inhibitors of erythropoiesis is extremely challenging, as the findings obtained by individual research teams are different. For this reason, opinions on the actual relevance of uremic toxins for the development of anemia remain contradictory for a variety of reasons. However, the work presented by A. Ersliev highlighted the role of uremic toxins in the development of anemia, as the author demonstrated using precise erythrokinesis studies that the response to recombinant EPO assessed according to the daily production of red blood cells decreased by half in stabilized, adequately dialyzed patients compared to healthy persons.

Renal anemia may be exacerbated by a lack of folic acid or Vitamin B12. Deficiency of Vitamin B12, or folic acid is uncommon, occurring in less than 10% of dialyzed patients. In these cases, it usually has a macrocytic pattern. Folic acid deficiency may occur particularly in dialyzed patients, because folic acid is dialyzable. Serum folate levels are also decreased after dialysis. The loss of folic acid during the dialysis outweighs the loss of folic acid in the urine of normal people, which is about 10 μg/24 h. The minimum recommended daily dose of folic acid is 50 μg.

A decrease in hemoglobin levels may occur in aluminum intoxication. In 1972, Alfrey described "dialysis encephalopathy" and four years later, scientists recognized its relation to aluminum intoxication. In 1978, Elliot and Macdougall first described a decrease in hemoglobin concentrations in patients with severe aluminum intoxication. Osteopathy, the third main clinical manifestation of aluminum toxicity, was described in 1980 by Pierides as Vitamin D-resistant osteomalacia. Anemia induced by the accumulation of aluminum has a microcytic and hypochromic character. Aluminum competes with iron for a binding site on the transferrin molecule, and its binding to free receptors increases, in particular in patients with iron deficiency. In addition, aluminum has been demonstrated to suppress the cytotoxic uroporphyrinogen decarboxylase and mitochondrial ferrochelatase. Worsening of anemia induced by the accumulation of aluminum is reversible and resolves after treatment with deferoxamine. Following the introduction of stringent standards for water purity and discontinuation of aluminum-containing phosphate binders, this phenomenon is virtually nil.

Hypoproliferative anemia may also be exacerbated by fibrous osteodystrophy, which is usually caused by severe secondary hyperparathyroidism. Excessive parathyormone levels are known to reduce EPO production, increase hemolysis, and suppress stem cells of the red blood cell line in the bone marrow.

Anemia may be further aggravated by drugs, particularly by ACE inhibitors. ACE inhibitors suppress the synthesis of erythropoietin in a dose-dependent manner.
via enhanced oxygenation in the peritubular region due to decrease in vascular resistance in efferent arterioles, decreased serum concentration of IGF-1 and increased apoptosis of progenitor erythroid cells CD 34+ (ref.60,61). Drugs are an important contributor to anemia in recipients of renal allografts. Anemia after kidney transplantation is a highly prevalent disorder affecting approximately 40% of patients and is predominantly associated with a decline of graft function. Immunosuppressants play an important additional role. Azathioprine, mycophenolate mofetil and mycophenolate sodium have a direct antiproliferative effect on bone marrow cells. Sirolimus and everolimus (mTOR inhibitors) can lead to microcytic anemia. Cyclosporine A and mTOR inhibitors are known to induce hemolytic uremic syndrome and hemolytic anemia in transplant patients. Another immunosuppressive agent, antithymocyte globulin (ATG) can decrease hemoglobin concentration via toxic effect on bone marrow62.

An additional factor associated with anemia is malnutrition. Severe hypoalbuminemia is associated with a significant impairment of the erythropoietic response. A link between malnutrition and anemia can be attributed to the malnutrition-inflammation complex syndrome (MIA syndrome) (ref.63). A working group KDIGO (Kidney Disease Improving Global Outcomes) published in August 2012 new recommendations for treating anemia in patients with CKD. The new recommendations have created many changes affecting clinical practice, in comparison to the previous American (KDOQI, 2006) and European (ERBP, 2004) ones. Newly recommended were higher serum levels of ferritin (500 μg/L) and for transferrin saturation (30%). Erythropoiesis stimulating agents (ESA) should be administered only following suitable supplementation of iron levels. Another important change is the lower recommended Hb concentration for which an intervention using ESA is indicated. ESA should be administered when Hb levels are in the range 90-100 g/L. In patients with symptoms of the anemic syndrome, ESA can be applied with Hb ≥ 100 g/L. It is generally recommended that during maintenance ESA therapy, the Hb level should not exceed 120 g/L in adult patients64. These guidelines also discussed causes of hyporesponsiveness and resistance to ESA, including iron deficiency, inflammation, malnutrition, lack of vitamin B12 and folic acid, secondary hyperparathyroidism, drugs and other topics concerning this important field in clinical nephrology which are discussed in detail in this review.

ACKNOWLEDGEMENT

Author contributions: Both authors contributed equally to preparing the manuscript.

Conflict of interest statement: The authors state that there are no conflicts of interest regarding the publication of this article.

REFERENCES
